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Introduction: Liver dysfunction can derive from severe sepsis and might be associated with poor prognosis.
However, diagnosis of septic liver dysfunction is challenging due to a lack of appropriate tests. Measurement of
maximal liver function capacity (LiMAx test) has been successfully evaluated as a new diagnostic test in liver
resection and transplantation. The aim of this study was to evaluate the LiMAx test during sepsis in comparison to
biochemical tests and the indocyanin green test (ICG-PDR).
Methods: We prospectively investigated 28 patients (8 female and 20 male, age range 35 to 80 years) suffering
from sepsis on a surgical ICU. All patients received routine resuscitation from septic shock (surgery, fluids,
catecholamines, antibiotic drugs). The first LiMAx test and ICG-PDR were carried out within the first 24 hours after
onset of septic symptoms, followed by day 2, 5 and 10. Other biochemical parameters and scores determining the
severity of illness were measured daily. Clinical outcome parameters were examined after 90 days or at the end of
treatment. The population was divided into 2 groups (group A: non-survivors or ICU length of stay (ICU-LOS) >30 days
versus group B: survivors and ICU-LOS <30 days) for analysis.
Results: Epidemiological baseline characteristics of both groups were similar. Group A patients had significant
lower LiMAx and ICG-PDR values than patients in group B. Determination of ICG-PDR by finger probe failed in
14.3% of tests due to insufficient peripheral pulses. Respiratory, renal and hepatic dysfunction (LiMAx and ICG-PDR)
were associated with prolonged ICU-LOS. Only LiMAx <100 μg/kg/h and respiratory dysfunction were associated
with increased mortality. For LiMAx <100 μg/kg/h receiver operating characteristic-analysis revealed a 100% sensitivity
and 77% specificity for death.
Conclusions: Sepsis-related hepatic dysfunction can be diagnosed early and effectively by the LiMAx test. The extent
of LiMAx impairment is predictive for patient morbidity and mortality. The sensitivity and specificity of the LiMAx test
was superior to that of ICG-PDR regarding the prediction of mortality.Introduction
Sepsis is a frequent infection with high mortality rates in
ICUs and may occur in approximately 25% of ICU pa-
tients. Multiple organ failure caused by sepsis still remains
the most frequent cause of death in intensive care [1]. Pa-
tients with septic shock develop liver failure in 19% [2]
with an increase up to 50% in case of acute hypoxic* Correspondence: magnus.kaffarnik@charite.de
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reproduction in any medium, provided the orhepatitis [3]. Hepatic dysfunction and liver failure indicate
poor outcome in critically ill patients [4,5]. Especially early
hepatic dysfunction is associated with higher in-hospital
mortality [6].
The diagnosis of liver dysfunction still remains imprecise.
Static tests such as serum bilirubin, alanine aminotransfer-
ase, aspartate aminotransferase and the International
Normalised Ratio (INR) are widely used for clinical routine
assessment of liver function and in intensive care scoring
systems. But there is a lack of studies evaluating the diag-
nostic and prognostic value of static liver dysfunction tests
on outcome in critically ill patients [7].l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to static tests for assessment of liver function [8]. The
plasma disappearance rate (hepatic clearance) of indo-
cyanine green (ICG-PDR) is widely used to determine
liver dysfunction in critically ill patients. Many authors
showed in several studies that ICG-PDR is correlated
with ICU survival [9,10]. Furthermore, ICG-PDR was su-
perior to different static liver function tests in terms of
outcome prediction and indicated liver dysfunction earl-
ier [11,12]. However, ICG-PDR has limitations due to
multiple confounding factors involved in indocyanine
green (ICG) clearance [13] and to the impact of several
factors such as hepatic blood flow and hyperbilirubine-
mia [14,15].
The new dynamic bedside test for maximal liver func-
tion capacity (LiMAx test) provides a non-invasive diag-
nostic tool for determining liver function in different
settings. The LiMAx test determines the maximal liver
function capacity based on a non-invasive breath test.
The test substrate is 13C-labeled methacetin that is ex-
clusively metabolized by cytochrome P450 1A2 into
13CO2 and acetaminophen. In several previous studies,
the LiMAx test was successfully evaluated as a diagnos-
tic test prior to and after liver resection and transplant-
ation [16-19].
In this study, we aimed to evaluate prospectively the
LiMAx test for diagnosis of hepatic dysfunction in a
well-defined cohort of patients with sepsis and compared
the results with ICG-PDR. Furthermore, we investigated




Patients suffering from bacterial sepsis were included in
a prospective observational study. The ethics review
board of the Charité medical faculty approved the study
protocol before the first patient was included. All partici-
pants or their responsible relatives gave written informed
consent prior to study inclusion.
Inclusion criteria were new onset of bacterial sepsis
(<24 hours) according to the current definition [20] and
age within 18 to 80 years. Exclusion criteria were pre-
existing advanced liver disease (for example, chronic hepa-
titis, liver fibrosis or cirrhosis), history of chemotherapy
(within 8 weeks prior to inclusion), history of daily cortisol
medication >5 mg, organ transplantation, or HIV.
All patients received routine sepsis therapy (surgery,
fluids, catecholamines, antibiotic drugs) according to the
current sepsis guidelines [21]. The Acute Physiology and
Chronic Health Evaluation II score was determined at
patient inclusion (first 24 hours) and the following pa-
rameters were obtained by clinical routine on a daily
basis from day 0 to day 10: Sequential Organ FailureAssessment score, Simplified Acute Physiology Score II,
serum and plasma laboratory parameters, blood gas ana-
lysis, hemodynamic parameters, body temperature, mech-
anical ventilation, hemodialysis and medication. Additional
diagnostic procedures including the LiMAx test and ICG-
PDR were performed at baseline (<24 hours after onset of
sepsis) and at days 2, 5, and 10 after inclusion of the pa-
tient. The patient follow-up was limited to 90 days or end
of treatment. After discharge of the patient, the duration
of mechanical ventilation and hemodialysis, the length of
stay (LOS) in the ICU and the different organ failures were
calculated.
Definitions of organ dysfunction
Cardiac dysfunction was defined as low cardiac output
by adequate volume supply (Cardiac index determined
by PiCCO™, Pulsion Medical Systems SE, Feldkirchin,
Germany) requiring continuous dobutamine infusion to
achieve a cardiac index ≥2.5 during days 0 to 5. He-
modynamic dysfunction was defined as arterial hypoten-
sion despite adequate volume supply requiring continuous
norepinephrine infusion to achieve a mean arterial pres-
sure ≥65 mmHg during days 0 to 5 [21]. Microcirculatory
dysfunction was defined as metabolic acidosis with serum
lactate >4.4 mmol/l during days 0 to 5 [22]. Respiratory
dysfunction was defined as respiratory insufficiency re-
quiring mechanical ventilation >24 hours during days 0 to
10. Renal dysfunction was defined according to the RIFLE
criteria [23]. Hematologic dysfunction was defined as
platelet count <100/nl [24]. Hepatic dysfunction was de-
fined as INR >1.5, increase of serum bilirubin ≥70 μmol/l
during days 0 to 10 [25-27], ICG-PDR ≤10.3%/minute
during days 0 to 10 [10], and LiMAx <100 μg/kg/hour
during days 0 to 10.
LiMAx test and plasma disappearance rate of indocyanine
green
The LiMAx test was performed as described previously
using the FLIP™ Analyzer (Humedics GmbH, Berlin,
Germany) [19]. 13C-labeled methacetin (Humedics GmbH)
was applied by an intravenous bolus of 2 mg/kg body
weight. The normal range was defined as >315 μg/kg/hour
[19]. In mechanically ventilated patients a special tube was
used to dissipate the exhaled gas to the 13CO2 detector.
ICG-PDR was performed by ICG pulse dye densitom-
etry using a commercially available analyzer (DDG-2001,
Dye Densitogram Analyzer; Nihon Kohden, Tokyo,
Japan) and a corresponding finger probe (DDG Analyzer
Finger Probe TL-301P; Nihon Kohden). ICG (ICG-Pul-
sion; Pulsion Medical Systems, Munich, Germany) was
applied by an intravenous bolus of 0.5 mg/kg body
weight. The normal range of ICG-PDR was defined as
18 to 25%/minute [9]. If patients were on continuous
hemodialysis, the injection of 13C-methacetin and ICG
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60 seconds to avoid recirculation and altered kinetics.
Statistical analysis
The primary analysis was based on the combined study
endpoint of negative clinical outcome, defined as sepsis-
related death or ICU LOS ≥30 days (group A). In contrast,
patients of group B survived sepsis and had ICU LOS
<30 days. A post-hoc power calculation based on the initial
LiMAx results (independent means in group A vs. group B;
α = 0.05, two-tailed, using G*Power 3.1, Heinrich Heine
University, Duesseldorf, Germany) yielded 1 – β = 0.979.
Data are presented as mean with standard deviation
and range, if not otherwise noted. Individual time points
were compared using repeated-measures analysis ofTable 1 Baseline characteristics
Group A
(patients deceased or ICU LOS ≥30 da
Patients 14










APACHE II score 34.9 ± 8.4 (18 to 49)
SAPS II score 59.1 ± 19.6 (23 to 90)
SOFA score 11.4 ± 4.8 (23 to 90)
Procalcitonin (ng/ml) 25.6 ± 25.6 (1.1 to 73)
C-reactive protein (mg/l) 184 ± 72 (91 to 330)
Temperature (°C) 37.2 ± 1.4 (35.0 to 39.5)
WBC (/nl) 20.6 ± 16.9 (1.1 to 46.6)
Heart rate (/minute) 112 ± 22 (80 to 160)
MAP (mmHg) 69.8 ± 7.6 (55 to 80)
Noradrenalin (μg/kg/minute) 0.42 ± 0.44 (0 to 1.50)
Dobutamine (μg/kg/minute) 1.3 ± 2.6 (0 to 8.7)
Lactate (mmol/l) 6.2 ± 5.5 (0.6 to 16.6)
pH 7.25 ± 0.10 (7.05 to 7.41)
Bilirubin (μmol/l) 22 ± 18 (5 to 63)
INR 1.7 ± 0.32 (1.39 to 2.44)
LiMAx (μg/kg/hour) 127 ± 88 (43 to 384)
ICG-PDR (%/minute) 8.8 ± 4.0 (3.4 to 16.9)
Data are presented as mean ± standard deviation (range). APACHE, Acute Physiolog
disappearance rate; INR, International Normalised Ratio; LiMAx, maximal liver functi
Acute Physiology Score; SOFA, Sequential Organ Failure Assessment; WBC: white blvariance. Group differences were compared by the ap-
propriate tests according to scale and data distribution,
including Fisher’s exact test, the chi-square test, and the
independent t test. The receiver operating characteristic
(ROC) curve was applied to calculate the best cutoff
value of minimum LiMAx during days 0 to 10 for predic-
tion of negative clinical outcome. Statistical significance
was considered P <0.05. Statistical analysis was performed
using IBM SPSS 19.0, Armonk, NY, USA.
Results
Twenty-eight of a total number of 185 potential patients
with new onset of sepsis were recruited during October
2011 and February 2013. The main exclusion criteria were
preexisting liver disease or history of chemotherapyys)
Group B
(patients survived and ICU LOS <30 days)
P valuea
14










19.1 ± 6.4 (10 to 27) <0.001
44.4 ± 16.1 (18 to 68) 0.043
6.9 ± 3.8 (0 to 13) 0.017
20.4 ± 27.3 (0.9 to 75) 0.60
139 ± 91 (40 to 290) 0.17
37.9 ± 0.9 (36.5 to 39.8) 0.14
10.4 ± 7.8 (1.4 to 27.3) 0.051
112 ± 26 (75 to 170) 0.91
69.4 ± 7.5 (55 to 85) 0.89
0.12 ± 0.09 (0 to 0.26) 0.024
0.3 ± 1.0 (0 to 3.8) 0.19
2.4 ± 1.8 (1 to 8.2) 0.028
7.33 ± 0.10 (7.03 to 7.45) 0.031
11 ± 13 (3 to 53) 0.084
1.35 ± 0.19 (1.13 to 1.69) 0.002
289 ± 117 (101 to 469) <0.001
25.0 ± 8.2 (14.3 to 39.6) <0.001
y and Chronic Health Evaluation; ICG-PDR, indocyanine green plasma
on capacity; LOS, length of stay; MAP, mean arterial pressure; SAPS, Simplified
ood cell count. aFisher’s exact test or independent t test.
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tion >5 mg (n = 32), refusal of participation (n = 13) and
unknown onset of sepsis or administrative reasons (n =
82). Sepsis was caused by secondary peritonitis (n = 15),
pneumonia (n = 9) or other foci (n = 4). The majority of
patients developed septic shock (n = 23, 85.7%) with
multiple organ dysfunction syndrome (n = 22, 78.6%).




Figure 1 Overall progression of dynamic liver parameters during sep
plasma disappearance rate (ICG-PDR). Bold lines, medians; box plots, 25th tduring sepsis: cardiac (n = 9, 32.1%), hemodynamic (n =
22, 8.6%), microcirculation (n = 9, 32.1%), respiratory (n =
17, 60.7%), renal injury (n = 14, 50%), renal failure (n = 11,
39.3%), hematologic (n = 11, 39.3%), and hepatic (n = 6,
21.4%). Nine patients (32.1%) required hemodialysis. Four
patients (14.3%) developed acute respiratory distress syn-
drome. Baseline characteristics of the admission day to








sis. (A) Maximal liver function capacity (LiMAx). (B) Indocyanine green
o 75th percentiles.
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group B were observed for the Acute Physiology and
Chronic Health Evaluation II score and the Sequential
Organ Failure Assessment score on admission and for epi-
nephrine dose, pH, serum lactate, INR, LiMAx and ICG-
PDR during the first day.
Hepatic dysfunction
The overall LiMAx values slightly dropped from baseline
(208 ± 131 μg/kg/hour) until day 2 (165 ± 93 μg/kg/hour;Figure 2 Progression of liver parameters by patient outcome. (A) Max
disappearance rate (ICG-PDR). Interrupted line, group A; continuous line, grP = 0.161), and then significantly recovered at day 5
(289 ± 190 μg/kg/h; P = 0.004) and at day 10 (357 ± 179;
P = 0.009; Figure 1A). The ICG-PDR was constant from
baseline to day 2 (17.6 ± 10.5 vs. 16.2 ± 10.3; P = 1.0),
increased slightly at day 5 (18.1 ± 9.6; P = 0.44), and re-
mained constant until day 10 (19.2 ± 8.7; P= 1.0; Figure 1B).
The determination of ICG-PDR by pulse dye densito-
metry with finger probe failed during 16 examinations
(14.3%) due to insufficient signal preferentially by im-
paired peripheral circulation (six times at baseline, threeimal liver function capacity (LiMAx). (B) Indocyanine green plasma
oup B. Mean values with 95% confidence interval. **P < 0.01.
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LiMAx measurements were valid. Serum bilirubin was
within normal range at baseline (16.7 ± 16.3 μmol/l; me-
dian 9.4 μmol/l) and slightly increased to a maximum at
day 6 (30.3 ± 42.8 μmol/l; median 10.3 μmol/l; P = 0.1).
Comparison of group A versus group B revealed signifi-
cant differences for LiMAx values at baseline (P <0.001),
day 2 (P <0.001), day 5 (P = 0.001) and day 10 (P = 0.004;
Figure 2A), and for ICG-PDR at baseline (P <0.001), day 2
(P = 0.001), and day 5 (P <0.001), but not at day 10 (P =
0.082; Figure 2B). In contrast, serum bilirubin levels be-
came significantly different between group A versus group
B at day 2 (P = 0.004) and remained different until day 10
(P <0.05). The vast majority of baseline LiMAx values
were already below normal range: overall 75%, group A
92.9% versus group B 57.1%. Baseline ICG-PDRs were
below normal range in 46.4% of overall patients: group A
71.4% versus group B 21.4%. In contrast, pathological
levels of serum bilirubin were observed in 25% of patients
at baseline (group A 42.9% vs. group B 7.1%) and the cu-
mulative incidence during 10 days was 50% (group A
78.6% vs. group B 21.4%). The incidence of hepatic dys-
function was therefore variable upon its definition (21.4%
by serum bilirubin, 35.7% by ICG-PDR, 39.3% by LiMAx,
53.6% by INR).
Length of stay and mortality
The ICU LOS was 33 ± 22 days (range 11 to 93 days).
Six patients (21.4%) died during 7 to 52 days after onset
of sepsis. In contrast, patients surviving sepsis were dis-
charged within 11 to 93 days. The impact of the particu-
lar organ dysfunctions on ICU LOS and mortality is
presented in Table 2. Occurrence of respiratory, renal or
hepatic dysfunction (defined by LiMAx and ICG-PDR)
was associated with prolonged ICU LOS. Occurrence of
respiratory or hepatic dysfunction (only LiMAx) wasTable 2 Impact of organ dysfunction on ICU LOS and mortalit
Dysfunction Definition
Cardiac Low cardiac output requiring dobutamine
Hemodynamic Hypotension requiring norepinephrine
Microcirculatory Serum lactate >4.4 mmol/l
Hematologic Platelet count <100/nl
Respiratory Respiratory insufficiency requiring ventilation >24 hours
Renal injury Serum creatinine >212 μmol/l or twofold increase
Failure Serum creatinine >318 μmol/l or threefold increase




ICG-PDR, indocyanine green plasma disappearance rate; INR, International Normalis
of sepsis. aPresence versus absence of organ failure. bIndependent t test. bFisher’s eassociated with increased mortality. The mortality was
0% in those patients without hemodynamic, respiratory
or hepatic dysfunction (defined by LiMAx).
The ROC analysis yielded a best cutoff value of
100 μg/kg/hour for prediction of negative outcome (area
under the ROC curve = 0.939; P <0.001). The sensitivity
for negative outcome was 78% with a specificity of 100%.
Three patients without hepatic dysfunction but all pa-
tients without hepatic dysfunction during the initial
10 days had a prolonged LOS. The positive predictive
value for negative outcome (group A) was 100% with a
negative predictive value (group B) of 82% (Figure 3). All
patients who died from sepsis (n = 6) but none of the
survivors revealed LiMAx values <100 μg/kg/hour dur-
ing 10 days after onset of sepsis (Figure 4A). LiMAx
values <100 μg/kg/hour thus also predicted death with
100% sensitivity and 77% specificity. The positive predict-
ive value was 54%; the negative predictive value was 100%.
Two patients developed LiMAx values <100 μg/kg/hour
at baseline, another two patients at day 2 and each one pa-
tients at day 5 and at day 10, respectively. In contrast,
ICG-PDR was associated with prolonged LOS but did not
predict survival (Figure 4B).
Recovery of liver function
Those patients (n = 5) who survived sepsis despite single
LiMAx values <100 μg/kg/hour revealed a significant
functional recovery in comparison with those patients
who deceased on day 5 (234 ± 170 vs. 123 ± 37; P =
0.032) and on day 10 (318 ± 163 vs. 168 ± 45; P = 0.042;
Figure 5A). However, two surviving patients showed ex-
ceptional LiMAx progressions: One patient yielded func-
tional recovery on day 5 but decreased again on day 10.
This patient suffered from esophageal perforation and
developed postoperative anastomosic leakage accompan-
ied with a second septic episode starting on day 8 withy
n (%) LOS (days)a P valueb Mortality (%)a P valueb
9 (32.1) 34 ± 24 vs. 33 ± 21 0.87 44.4 vs. 10.5 0.064
22 (78.6) 37 ± 23 vs. 19 ± 10 0.067 27.3 vs. 0.0 0.20
9 (32.1) 34 ± 24 vs. 32 ± 22 0.85 44.4 vs. 10.5 0.064
11 (39.3) 40 ± 24 vs. 28 ± 20 0.18 27.3 vs. 17.6 0.44
17 (60.7) 41 ± 24 vs. 21 ± 10 0.009 35.3 vs. 0.0 0.033
14 (50) 40 ± 26 vs. 27 ± 15 0.121 28.6 vs. 14.3 0.32
11 (39) 46 ± 25 vs. 25 ± 14 0.021 36.4 vs. 11.8 0.14
6 (21.4) 47 ± 31 vs. 29 ± 17 0.24 33.3 vs. 18.2 0.38
15 (53.6) 40 ± 25 vs. 26 ± 14 0.09 26.7 vs. 15.4 0.40
10 (35.7) 48 ± 21 vs. 25 ± 17 0.005 40.0 vs. 11.1 0.098
11 (39.3) 44 ± 19 vs. 26 ± 21 0.028 54.5 vs. 0.0 0.001
ed Ratio; LiMAx, maximal liver function capacity; LOS, length of stay after onset
xact test.
Figure 3 Receiver operating characteristic curve for prediction
of negative outcome by maximal liver function capacity test.
Sensitivity and specificity of maximal liver function capacity
(LiMAx) <100 μg/kg/hour for prediction of negative outcome
(patients deceased or ICU length of stay ≥30 days). AUROC,
area under the receiver operating characteristic curve.
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LiMAx values <100 μg/kg/hour during days 0 to 5, but
thereafter the LiMAx increased slowly. This patient suf-
fered from a severe sepsis with four-organ failure. The
serum bilirubin increased up to 106 μmol/l on day 8.
The patient ultimately recovered and was discharged
after 77 days. In contrast, the majority of patients with
LiMAx values >100 μg/kg/hour yielded fast recovery of
liver function already on day 5. Those three patients
with prolonged ICU LOS despite absence of hepatic
dysfunction yielded either borderline dysfunction with
decelerated recovery or prolonged deterioration of hep-
atic function until day 5 (Figure 5B).Discussion
The present study investigated the LiMAx test for diag-
nosis of sepsis-related hepatic dysfunction for the first
time. The results clearly show that septic shock leads to
pathologic deterioration of LiMAx within 2 days after
onset of sepsis in the vast majority of patients. Further-
more, the LiMAx test indicates functional recovery
within 10 days, while ICG-PDR and serum bilirubin
levels remain almost constant during that period of time.
There is also evidence that the degree of functional im-
pairment determined by LiMAx is closely related to the pa-
tients’ prognosis. Patients with negative clinical outcome
revealed significantly decreased LiMAx values in compari-
son with those patients who quickly recovered. Patients
with LiMAx values <100 μg/kg/hour revealed a mortality
rate of 55%, whereas patients with values >100 μg/kg/hourhad a mortality of 0%. In addition, follow-up LiMAx
allowed the determination of individual progress of the
patients.
Since the LiMAx test had already provided promising
results for the assessment of liver function in liver resec-
tion and transplantation [16-19], the aim of this study
was to explore its diagnostic potential during sepsis. The
well-described ICG-PDR was applied as a comparator.
Although both tests are known as dynamic liver function
tests, the LiMAx test determines the metabolic capacity
based on the cytochrome P450 system (1A2), whereas
ICG-PDR reflects the elimination of ICG into the bile,
which is a transport function and not a metabolic
function.
Patients were asked to participate in the study directly
after onset of septic symptoms. However, the time inter-
val between onset of sepsis and the testing by LiMAx
and ICG-PDR was limited to 24 hours for administrative
issues. The dynamic liver function tests were repeated
after 2, 5 and 10 days to elude the progression of liver
function in that crucial period. The aim was to compare
liver function parameters with the clinical outcome, in
particular mortality and the ICU LOS.
The LiMAx values yielded an interesting progression
during 10 days. The wide range of test readouts at the
baseline visit might be attributable to the variable inter-
val from onset of symptoms to testing. The impact of
sepsis, systemic inflammation and hypotension seems to
have a very early effect on metabolic liver function. This
effect cannot be described by biochemical parameters
such as serum bilirubin, which is well within normal
range at that time point and reaches maximum values as
late as after 6 days. Furthermore, the early impairment
of ICG-PDR might be mainly caused by impaired hepatic
blood flow due to hypotension. Interestingly, the major-
ity of patients yielded normal ICG-PDR results during
sepsis, whereas 90% of patients had impaired LiMAx
readouts. Stehr and colleagues described similar results
in a model of septic porcines, where a discrepancy be-
tween ICG-PDR (normal) and biliary ICG excretion (de-
creased) was observed. These authors assumed complex
ICG kinetics, especially in patients with liver disease,
and temporary redistribution of ICG into extrahepatic–
extravascular tissues as reasons for a false high ICG-PDR
in sepsis. They came to the conclusion that ICG-PDR may
not accurately measure liver dysfunction in sepsis [15].
The further progression of LiMAx yielded a nadir within
2 days followed by a fast recovery within 10 days, when
the majority of patients had regained normal function.
This finding confirms previous studies describing the fast
functional recovery after liver resection [19]. The LiMAx
test thus appears to be superior to follow-up liver function
in comparison with ICG-PDR and static parameters such
as serum bilirubin.
AB
Figure 4 Survival and hepatic dysfunction. Kaplan–Meier curve for 90-day patient survival divided by (A) minimum maximal liver function
capacity (LiMAx) <100 μg/kg/hour and (B) minimum indocyanine green plasma disappearance rate (ICG-PDR) ≤10.3%/minute. Log-rank test was
applied for analysis.
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ical outcome showed that both LiMAx and ICG-PDR im-
pairment predicted prolonged ICU LOS, but only LiMAx
values <100 μg/kg/hour predicted mortality. Serum biliru-
bin and INR failed to differentiate between deceased and
surviving patients in terms of ICU LOS and survival.
These findings confirm the validity of the LiMAx test due
to prediction of mortality in patients with liver failure.
Interestingly, the chosen cutoff value in sepsis seems com-
parable with that described after liver resection, where
values <100 μg/kg/hour were associated with a very high
mortality rate [17].
In our study population, serum bilirubin levels failed
to differentiate between survivors or nonsurvivors/ICU
LOS >30 days at any time point of the 10 days beforedischarge or death. These results are in line with simi-
lar contributions related to the impact of bilirubin
levels in septic patients [9,26]. In a prospective study,
Kramer and colleagues found early hyperbilirubinemia
(bilirubin >34.2 μmol/l in the first 48 hours) to be a
strong independent risk factor for mortality. In the
large study population, only 11% of patients developed
early hyperbilirubinemia [6]. Our data support the evi-
dence that early liver dysfunction without evidence in clin-
ical routine parameters occurs more frequently in the
course of sepsis. These findings are in concert with the re-
sults of Recknagel and colleagues. The authors described
an impaired hepatic biotransformation within hours after
onset of sepsis and cholestasis (hyperbilirubinemia) as an






































Figure 5 Maximal liver function capacity progression of
individual patients. (A) Patients with minimum maximal liver
function capacity (LiMAx) < 100 μg/kg/hour. Bold lines, patients who
survived; interrupted lines, patients who died from sepsis. (B)
Patients with minimum LiMAx ≥100 μg/kg/hour. Bold lines, patients
of group B (survived and ICU length of stay (LOS) <30 days);
interrupted lines, patients of group A (deceased or ICU
LOS ≥30 days).
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and colleagues found in ROC analysis a higher area under
the curve with respect to outcome for the ICG-PDR when
using the lowest value in critically ill patients [10]. Other
authors confirmed these results in septic patients and in
patients after liver transplantation [29,30]. ROC statistics
of our study according to mortality show a higher sensitiv-
ity of the LiMAx test (100%) compared with the ICG-PDR
(70%) with a similar specificity (77% vs. 80%) [10]. The
LiMAx test thus seems to be equal to the ICG-PDR test in
detecting early liver dysfunction in sepsis; and among all
investigated liver function tests in the present study,
LiMAx <100 μg/kg/hour appears the most reliable par-
ameter to predict mortality.
The reduction of hepatic blood flow is still considered
the main cause of liver failure in sepsis, and liver failure
is traditionally considered a late manifestation of sepsis-
induced multiple organ failure [7]. In the past years,several studies described septic transformation in hepatic
function besides an impaired hepatic blood flow. Carcillo
and colleagues demonstrated a reduced detoxification
system of several cytochrome P enzymes in septic pa-
tients [31]. Recent data implicate the importance of early
detection of liver failure in sepsis. Recknagel and col-
leagues described in a rodent model the impact of im-
paired hepatobiliary transport and a defect in the hepatic
detoxification system, including the cytochrome P450
enzyme family, with the result of a reduced xenobiotic
biotransformation. This transformation will lead to im-
paired detoxification of substances that are normally bile
excreted [28]. These findings give evidence that not only
a decreased hepatic blood flow causes liver failure in
sepsis. Also, processes involving the hepatobiliary trans-
port and the biotransformation based on the cytochrome
P450 family may predict the progression of liver failure
in septic patients. To evaluate the impact of these
changes, the metabolism of methacetin by cytochrome
P450 1A2 may be helpful to quantify the degree of liver
failure. From a methodological point of view it is un-
likely that changes in liver perfusion above the level
where cellular functional alterations takes place influ-
ence the LiMAx result since no clearance is measured
apart from the formation of a metabolic product. How-
ever, actually this question cannot be answered systemat-
ically based on solid experimental data. On the other
side, it is well known that the ICG-PDR not only de-
scribes the liver function but is severely influenced by
the splanchnic perfusion [32]. ICG-PDR uptake and
elimination in the liver is based on a carrier transport
and do not reflect the changes in cytochrome P450 [33,34].
Moreover, ICG elimination is inhibited by hyperbilirubine-
mia (>56 μmol/l) and other anionic substances and leads
to false lower ICG-PDR results [34,35] Furthermore, ICG-
PDR is influenced by acute cholestasis without evidence of
changes in hemodynamic or morphology of hepatozytes
and, as mentioned above, by complex ICG kinetics and a
temporary redistribution of ICG into extrahepatic, extra-
vascular tissues [15,36,37]. The LiMAx test may therefore
provide a more sophisticated tool to detect early liver dys-
function in critically ill patients.
Transformation of these findings into clinical routine
or decision-making is a challenge. The patient popula-
tion in our study is too small to establish clinical guide-
lines. Furthermore, no specific therapies improving the
hepatic function in patients with septic liver failure are
currently established. The main effort of clinicians should
focus on identifying and reversing the underlying disease
and stabilize the hepatic function as early as possible
[38,39]. To improve the hepatic function, hepatotoxic drugs
and therapies should be avoided and in special cases an
extracorporeal liver support may be helpful. Thus, when
LiMAx <100 μg/kg/hour during sepsis resuscitation
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clinician of the need for more extreme interventions.
However, the impact of hepatic dysfunction on therapy
during sepsis may be underestimated at present. Especially
the pharmacokinetics of many predominantly hepatic me-
tabolized drugs remains unclear (for example, antibiotics,
antimycotics). Kruger and colleagues described increased
drug-levels of atorvastatin in septic patients [40]. Based on
the increasing concern about toxicity of administered
drugs in patients with organ failure, early detection of
liver failure may become an influence on drug dosage,
when plasma levels of drugs would be measured [41].
The conclusions of the present study are somehow
limited due to the relative small patient population and
the fact that most patients suffered from peritonitis. In
addition, the LiMAx cutoff value was post-hoc chosen and
requires prospective confirmation. Since all tests were
performed after the onset of sepsis, the individual values
before sepsis remain unknown. In addition, no data are
available about potential long-term effects on liver func-
tion beyond 10 days after onset of sepsis. Furthermore,
the determination of ICG-PDR failed in 14% of examina-
tions due to insufficient peripheral pulses using the finger
probe. Potentially the application of a nasal septum sensor
might have reduced the number of missing values. Previ-
ous ICG-PDR studies investigating critically ill patients
did not report any number of test failures [9,10,42].
Conclusions
The results of this study indicate that the LiMAx test
provides an adequate tool to determine early liver dys-
function in sepsis and was found to be a good predictor
of survival in septic patients. The LiMAx test is equal or
superior (due to prediction of death) to the ICG-PDR
and superior to established static liver function tests. Be-
cause of the cytochrome P450 metabolism of the test
substrate methacetin, the LiMAx test may detect liver
dysfunction in sepsis earlier and better reflect the so-
phisticated processes triggered by sepsis in the liver.
Key messages
 The LiMAx test, a new dynamic liver function test,
is an adequate tool for early detection of liver
function in septic patients.
 The LiMAx test is equal to the ICG-PDR in terms
of detection of liver function and is superior due to
prediction of death in septic patients.
 LiMAx <100 μg/kg/hour during sepsis resuscitation
may indicate a poor prognosis.
 Cytochrome P450 metabolism of the test substrate
methacetin may reflect better the complex, sepsis-
triggered processes in the liver in contrast to ICG
elimination, based on carrier transport.Abbreviations
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